BioSpace News Archive

The nation’s opioid epidemic resulted in the opioid overdose deaths of almost 48,000 Americans in 2017.

It apparently began with a 2016 federal lawsuit. At that time, 20 state attorneys general filed a federal lawsuit alleging that six generic drug makers artificially inflated and manipulated prices for an antibiotic and an oral diabetes drug. The goal was to reduce competition.

This morning the Pharmaceutical Research and Manufacturers of America (PhRMA) released a report that shows there are nearly 300 novel cell and gene therapies currently in development throughout the industry. The therapies are being studied as treatments for a variety of diseases and conditions.

Pharming Group N.V. today acknowledged presentation of the results from an investigator-initiated comparative study of therapies in acute attacks of hereditary angioedema (“HAE”).

The U.S. Food and Drug Administration (FDA) has issued an approval letter for the new features and intended uses of the Planmed Verity® CBCT scanner. Planmed is very pleased to bring these exciting improvements to the U.S. market.

The board of directors of Medtronic plc (NYSE:MDT) today approved the fiscal year 2019 third quarter cash dividend of $0.50 per ordinary share, representing a 9 percent increase over the prior year.

MorphoSys AG announced today that according to the title of a presentation to be held next Wednesday afternoon CET (December 12, 2018) at the upcoming Inflammatory Skin Disease Summit (ISDS) conference in Vienna, Austria, guselkumab [Tremfya(R)] demonstrates superior long-term responses to secukinumab [Cosentyx(R)] at Week 48 in the treatment of moderate to severe psoriasis, as results from the ECLIPSE trial.

The Best Biotech Entrepreneur Award® goes to Gilles Avenard, CEO of Acticor Biotech

More journal articles are revealed to lack full disclosure of the authors’ ties to the pharmaceutical industry.

Gilead Sciences officially announced that long-time Roche veteran, Daniel O’Day, will assume the helm of the company as chairman and chief executive officer beginning March 1. O’Day takes over for John Milligan, who announced his plans to retire by the end of the year in July.